Unlock instant, AI-driven research and patent intelligence for your innovation.

Combination therapy of a type II anti-CD20 antibody with an anti-Bcl-2 active agent

A combination therapy, bcl-2 technology, applied in the direction of antibody medical ingredients, antibodies, organic active ingredients, etc.

Inactive Publication Date: 2010-09-08
ROCHE GLYCART AG
View PDF22 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In a review in (Lucken-Ardjomande, S., and Martinou, J.C., J Cell Sci (Journal of Cell Science) 118 (2005) 473-483), several unrelated peptides / proteins have been proposed to regulate Bax activity, but their physiological Linkages still need to be established

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy of a type II anti-CD20 antibody with an anti-Bcl-2 active agent
  • Combination therapy of a type II anti-CD20 antibody with an anti-Bcl-2 active agent
  • Combination therapy of a type II anti-CD20 antibody with an anti-Bcl-2 active agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0022] The term "antibody" encompasses various forms of antibodies including, but not limited to, whole antibodies, human antibodies, humanized antibodies, and genetically engineered antibodies such as monoclonal, chimeric, or recombinant antibodies, as well as fragments of these antibodies, as long as they retain According to the characteristic of the present invention.

[0023] The term "monoclonal antibody" or "monoclonal antibody composition" as used herein refers to a preparation of antibody molecules having a single amino acid composition. Thus, the term "human monoclonal antibody" refers to an antibody displaying a single binding specificity having variable and constant regions derived from human germline immunoglobulin sequences, in one embodiment, a human monoclonal antibody is produced by a hybridoma , the hybridoma comprising a B cell obtained from a transgenic non-human animal, eg, a transgenic mouse, having a genome comprising a human heavy chain transgene and a l...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is directed to the use of a type II anti-CD20 antibody for the manufacture of a medicament for the treatment of cancer, especially of CD20 expressing cancers in combination with an anti-Bcl-2 active agent.

Description

[0001] The present invention relates to the application of type II anti-CD20 antibody in the preparation of a drug for combined treatment of cancer, especially CD20-expressing cancer, with an anti-Bcl-2 active agent. Background of the invention [0002] The CD20 molecule (also known as human B lymphocyte-restricted differentiation antigen or Bp35) is a hydrophobic transmembrane protein with a molecular weight of about 35 kD located on pre-B (pre-B) and mature B lymphocytes (Valentine, M.A. et al., J . Biol. Chem. 264(19)(1989) 11282-11287; and Einfield, D.A. et al., EMBO J. 7(3)(1988) 711-717). CD20 is found on the surface of more than 90% of B cells from peripheral blood or lymphoid organs, is expressed during early pre-B cell development and persists until plasma cell differentiation. CD20 is present on normal B cells as well as malignant B cells. Specifically, CD20 is expressed on more than 90% of B-cell non-Hodgkin's lymphomas (NHL) (Anderson, K.C. et al., Blood 63(6) (19...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61P35/00
CPCA61K31/495A61K39/39558A61K2039/505C07K16/2887A61K39/39533A61K45/06A61P35/00A61P35/04A61P43/00A61K2300/00
Inventor 托马斯·弗里斯克里斯蒂安·克莱因帕梅拉·布雷姆巴勃罗·乌马纳
Owner ROCHE GLYCART AG